Brokerages Set Astrana Health, Inc. (NASDAQ:ASTH) PT at $38.88

Shares of Astrana Health, Inc. (NASDAQ:ASTH) have been assigned an average recommendation of “Hold” from the eight analysts that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $35.3333.

ASTH has been the subject of several recent research reports. Zacks Research lowered Astrana Health from a “hold” rating to a “strong sell” rating in a research report on Tuesday, February 10th. Needham & Company LLC initiated coverage on Astrana Health in a research note on Friday, December 12th. They issued a “buy” rating and a $28.00 price objective for the company. BTIG Research cut their target price on Astrana Health from $45.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. TD Cowen decreased their price target on Astrana Health from $40.00 to $35.00 and set a “buy” rating on the stock in a report on Monday, November 10th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Astrana Health in a research note on Monday, December 29th.

Astrana Health News Roundup

Here are the key news stories impacting Astrana Health this week:

• Positive Sentiment: Q4 results beat expectations: Astrana reported strong revenue growth (revenue ~$950.5M, +42.9% y/y) and reported EPS above consensus, a key fundamental positive that initially drove buying interest. Astrana Health, Inc. Reports Fourth Quarter and Year End 2025 Results
• Positive Sentiment: Market reaction to the print and guidance was initially upbeat: coverage noted the stock rose after the results and management’s outlook. That short-term momentum can support near-term buying interest. Astrana Health stock rises above 3% on earnings beat and strong guidance
• Neutral Sentiment: Management will speak at investor conferences (TD Cowen fireside chat), improving visibility with institutional investors but not an immediate earnings driver. Astrana Health, Inc. to Participate in Upcoming Investor Conferences
• Neutral Sentiment: Revenue guidance provided (FY revenue range ~ $3.8B–$4.1B; Q1 revenue range ~$900M–$1.0B) — the ranges roughly bracket consensus but are wide, leaving room for interpretation and volatility as analysts refine models.
• Neutral Sentiment: Short-interest reporting appears anomalous (entries showing 0 shares / NaN changes and 0.0 days to cover), suggesting data noise rather than a material short-squeeze signal; ignore until clearer updates.
• Negative Sentiment: Conflicting earnings-call transcripts (some reports show a smaller EPS/miss) have circulated, creating investor confusion and likely short-term selling/volatility despite the company’s official release. Astrana Health, Inc. Q4 2025 Earnings Call Transcript

Hedge Funds Weigh In On Astrana Health

Several hedge funds have recently added to or reduced their stakes in ASTH. Signaturefd LLC lifted its stake in Astrana Health by 57.9% in the fourth quarter. Signaturefd LLC now owns 1,058 shares of the company’s stock worth $26,000 after purchasing an additional 388 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Astrana Health by 144.7% in the fourth quarter. GAMMA Investing LLC now owns 1,473 shares of the company’s stock worth $37,000 after buying an additional 871 shares during the period. Strs Ohio bought a new stake in shares of Astrana Health during the 4th quarter worth approximately $40,000. Covestor Ltd boosted its holdings in Astrana Health by 210.6% during the 3rd quarter. Covestor Ltd now owns 3,233 shares of the company’s stock valued at $92,000 after acquiring an additional 2,192 shares during the period. Finally, Tower Research Capital LLC TRC boosted its holdings in Astrana Health by 323.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock valued at $115,000 after acquiring an additional 3,517 shares during the period. 52.77% of the stock is currently owned by institutional investors.

Astrana Health Trading Down 6.9%

Shares of ASTH opened at $24.51 on Wednesday. The stock has a market capitalization of $1.38 billion, a PE ratio of 53.28, a P/E/G ratio of 0.78 and a beta of 0.91. The company’s fifty day moving average is $23.56 and its 200 day moving average is $26.24. The company has a debt-to-equity ratio of 1.27, a quick ratio of 1.40 and a current ratio of 1.40. Astrana Health has a fifty-two week low of $18.08 and a fifty-two week high of $34.80.

Astrana Health (NASDAQ:ASTH) last released its quarterly earnings data on Monday, March 2nd. The company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.15 by $0.39. Astrana Health had a net margin of 0.71% and a return on equity of 5.63%. The business had revenue of $950.53 million during the quarter, compared to analyst estimates of $930.46 million. During the same quarter last year, the business earned ($0.15) earnings per share. Astrana Health’s quarterly revenue was up 42.9% compared to the same quarter last year. Sell-side analysts expect that Astrana Health will post 1.15 earnings per share for the current fiscal year.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.